alexa
Reach Us +44-1647-403003
Treatment of Infiltrative Basal Cell Carcinomas by inhibiting the Fibroblast Growth Factor (FGF)-Signal Transducer and Activator of Transcription (STAT)-3 Signalling Pathways | Abstract
ISSN: 1948-5956

Journal of Cancer Science & Therapy
Open Access

Like us on:

Our Group organises 3000+ Global Conferenceseries Events every year across USA, Europe & Asia with support from 1000 more scientific Societies and Publishes 700+ Open Access Journals which contains over 50000 eminent personalities, reputed scientists as editorial board members.

Open Access Journals gaining more Readers and Citations
700 Journals and 15,000,000 Readers Each Journal is getting 25,000+ Readers

This Readership is 10 times more when compared to other Subscription Journals (Source: Google Analytics)

Commentary

Treatment of Infiltrative Basal Cell Carcinomas by inhibiting the Fibroblast Growth Factor (FGF)-Signal Transducer and Activator of Transcription (STAT)-3 Signalling Pathways

Pedro Cuevas1*, Javier Angulo1, Adrián Cuevas-Bourdier2, Irene Salgüero3 and Guillermo Giménez-Gallego4

1Departamento de Investigación. Servicio de Histología

2Servicio de Anatomía Patológica

3Servicio de Dermatología Hospital Universitario Ramón y Cajal, IRYCIS, E-28034-Madrid-Spain

4Departamento de Estructura y Función de Proteínas. Centro de Investigaciones Biológicas Consejo Superior de Investigaciones Científicas. (CSIC), Madrid

*Corresponding Author:
Dr. Pedro Cuevas
Servicio de Histología
Departamento de Investigación
IRYCIS, Hospital Universitario Ramón y Cajal
Ctra. de Colmenar,km. 9.100, E2034-Madrid-Spain
E-mail: [email protected]

Received Date: September 23, 2011; Accepted Date: November 05, 2011; Published Date: November 07, 2011

Citation: Cuevas P, Angulo J, Cuevas-Bourdier A, Salgüero I, Giménez-Gallego G (2011) Treatment of Infiltrative Basal Cell Carcinomas by inhibiting the Fibroblast Growth Factor (FGF)-Signal Transducer and Activator of Transcription (STAT)-3 Signalling Pathways. J Cancer Sci Ther S3:003. doi:10.4172/1948-5956.S3-003

Copyright: © 2011 Cuevas P, et al. This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.

Abstract

Over-expression of FGF/STAT-3 signalling pathways or aberrant regulation of their activities has been implicated in many forms of human malignancies, including skin neoplasms. Therefore, targeting FGF/STAT-3 signalling pathways represents an attractive strategy for development of basal cell carcinoma (BCC) treatment by simultaneously inhibiting tumor cell growth and survival, and also tumor angiogenesis. Here, we describe the efficacy of a safe, potent and selective FGF inhibitor –dobesilate- in BCC patients. Anti-tumor effect of dobesilate correlates with promotion of apoptosis, and inhibition of both cell proliferation and angiogenesis. Our data support dobesilate as an agent for chemoprevention and therapy of skin cancers by inhibiting FGF/STAT-3 oncogenic signalling axis.

Keywords

Share This Page
Top